ArticleJournal of neuro-oncology2006
Glioma-produced extracellular matrix influences brain tumor tropism of human neural stem cells.
Article in Journal of neuro-oncology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.
- Influence of glioblastoma contact with the lateral ventricle on survival: a meta-analysis.Journal of neuro-oncology · 2017Pooled it
- The Extracellular Matrix, the Silent 'Architect' of Glioma.Biomedicines · 2026Review
- Anti-Metastatic Effects of Aprepitant on Glioblastoma Cells: Targeting the Substance P/Neurokinin-1 Pathway.Cancer medicine · 2025Article
- IDH1 R132H and TP53 R248Q Mutations Modulate Glioma Cell Migration and Adhesion on Different ECM Components.International journal of molecular sciences · 2024Article
- Mesenchymal stem cells: a trojan horse to treat glioblastoma.Investigational new drugs · 2023Review
- To Explore the Stem Cells Homing to GBM: The Rise to the Occasion.Biomedicines · 2022Review
- Progress in mimicking brain microenvironments to understand and treat neurological disorders.APL bioengineering · 2021Article
- Allogeneic human neural stem cells for improved therapeutic delivery to peritoneal ovarian cancer.Stem cell research & therapy · 2021Article
- Neural Stem Cell-Based Therapies and Glioblastoma Management: Current Evidence and Clinical Challenges.International journal of molecular sciences · 2021Review
- Quantitative Evaluation of Intraventricular Delivery of Therapeutic Neural Stem Cells to Orthotopic Glioma.Frontiers in oncology · 2019Article
- Concise Review: Neural Stem Cell-Mediated Targeted Cancer Therapies.Stem cells translational medicine · 2018Review
- Intranasal delivery of stem cell-based therapies for the treatment of brain malignancies.Expert opinion on drug delivery · 2018Review
- Long-term stability and computational analysis of migration patterns of L-MYC immortalized neural stem cells in the brain.PloS one · 2018Article
- Human Neural Stem Cell Biodistribution and Predicted Tumor Coverage by a Diffusible Therapeutic in a Mouse Glioma Model.Stem cells translational medicine · 2017Article
- Targeting Malignant Brain Tumors with Antibodies.Frontiers in immunology · 2017Review
- A non-aggressive, highly efficient, enzymatic method for dissociation of human brain-tumors and brain-tissues to viable single-cells.BMC neuroscience · 2016Article
- Implications of irradiating the subventricular zone stem cell niche.Stem cell research · 2016Review
- Dynamic regulation of platelet-derived growth factor D (PDGF-D) activity and extracellular spatial distribution by matriptase-mediated proteolysis.The Journal of biological chemistry · 2015Article
- Neurosphere and adherent culture conditions are equivalent for malignant glioma stem cell lines.Anatomy & cell biology · 2015Article
- In Silico Neuro-Oncology: Brownian Motion-Based Mathematical Treatment as a Potential Platform for Modeling the Infiltration of Glioma Cells into Normal Brain Tissue.Cancer informatics · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A major obstacle in the treatment of gliomas is the invasive capacity of the tumor cells. Previous studies have demonstrated the capability of neural stem cells (NSCs) to target these disseminated tumor cells and to serve as therapeutic delivery vehicles. Less is known about the factors involved in brain tumor tropism of NSCs and their interactions within the tumor environment. As gliomas progress and invade, an extensive modulation of the extracellular matrix (ECM) occurs. Tumor-ECM derived from six glioblastoma cell lines, ECM produced by normal human astrocytes and purified ECM compounds known to be upregulated in the glioma environment were analyzed for their effects on NSCs motility in vitro. We found that tumor-produced ECM was highly permissive for NSC migration. Laminin was the most permissive substrate for human NSC migration, and tenascin-C the strongest inducer of a directed human NSC migration (haptotaxis). A positive correlation between the degree of adhesion and migration of NSCs on different ECM compounds exists, as for glioma cells. Our in vitro data suggest that the ECM of malignant gliomas is a modulator of NSC migration. ECM proteins preferentially expressed in areas of glioma cell invasion may provide a permissive environment for NSC tropism to disseminated tumor cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.